{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:49:46Z","timestamp":1790830186290,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF\/Pink Ribbon 11704"],"award-info":[{"award-number":["KWF\/Pink Ribbon 11704"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF-CRAFT 12754"],"award-info":[{"award-number":["KWF-CRAFT 12754"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.trecan.2022.04.009","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T11:12:54Z","timestamp":1653477174000},"page":"759-770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["CHEK2 variants: linking functional impact to cancer risk"],"prefix":"10.1016","volume":"8","author":[{"given":"Rick A.C.M.","family":"Boonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike P.G.","family":"Vreeswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-0240","authenticated-orcid":false,"given":"Haico","family":"van Attikum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2022.04.009_bb0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","article-title":"Linkage of ATM to cell cycle regulation by the Chk2 protein kinase","volume":"282","author":"Matsuoka","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.trecan.2022.04.009_bb0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1101\/gad.14.3.278","article-title":"Chk2\/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53","volume":"14","author":"Chehab","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.trecan.2022.04.009_bb0015","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1126\/science.286.5449.2528","article-title":"Heterozygous germ line hCHK2 mutations in Li\u2013Fraumeni syndrome","volume":"286","author":"Bell","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.trecan.2022.04.009_bb0020","article-title":"Li\u2013Fraumeni syndrome","author":"Schneider","year":"1999","journal-title":"GeneReviews"},{"key":"10.1016\/j.trecan.2022.04.009_bb0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","article-title":"Li\u2013Fraumeni syndrome: cancer risk assessment and clinical management","volume":"11","author":"McBride","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2022.04.009_bb0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes \u2013 association analysis in more than 113,000 women","volume":"384","author":"Breast Cancer Association Consortium","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2022.04.009_bb0035","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","article-title":"Associations between cancer predisposition testing panel genes and breast cancer","volume":"3","author":"Couch","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2022.04.009_bb0040","doi-asserted-by":"crossref","first-page":"7327","DOI":"10.1136\/jmedgenet-2017-104588","article-title":"Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks","volume":"54","author":"Decker","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0045","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cam4.1376","article-title":"Gene panel testing of 5589 BRCA1\/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer","volume":"7","author":"Hauke","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.trecan.2022.04.009_bb0050","first-page":"555","article-title":"Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations","volume":"31","author":"Meijers-Heijboer","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0055","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.2005.05.5160","article-title":"Increased risk of breast cancer associated with CHEK2*1100delC","volume":"25","author":"Weischer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2022.04.009_bb0060","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0065","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3390\/cells9122675","article-title":"CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate","volume":"9","author":"Stolarova","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.trecan.2022.04.009_bb0070","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2022.04.009_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13073-019-0690-2","article-title":"Recommendations for application of the functional evidence PS3\/BS3 criterion using the ACMG\/AMP sequence variant interpretation framework","volume":"12","author":"Brnich","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.trecan.2022.04.009_bb0080","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/ijc.23026","article-title":"Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts","volume":"121","author":"Bell","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2022.04.009_bb0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1158\/0008-5472.CAN-21-1845","article-title":"Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk","volume":"82","author":"Boonen","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.04.009_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003062","article-title":"CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer","volume":"3","author":"Chrisanthar","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.trecan.2022.04.009_bb0095","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2021.01.041","article-title":"Functional interrogation of DNA damage response variants with base editing screens","volume":"184","author":"Cuella-Martin","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.trecan.2022.04.009_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/humu.23728","article-title":"Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system","volume":"40","author":"Delimitsou","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.trecan.2022.04.009_bb0105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/35071124","article-title":"The ATM\u2013Chk2\u2013Cdc25A checkpoint pathway guards against radioresistant DNA synthesis","volume":"410","author":"Falck","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.04.009_bb0110","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/ijc.32385","article-title":"Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer","volume":"145","author":"Kleiblova","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.trecan.2022.04.009_bb0115","first-page":"8062","article-title":"Destabilization of CHK2 by a missense mutation associated with Li\u2013Fraumeni Syndrome","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.04.009_bb0120","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/dds101","article-title":"Response to DNA damage of CHEK2 missense mutations in familial breast cancer","volume":"21","author":"Roeb","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi052","article-title":"Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population","volume":"14","author":"Shaag","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0130","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2008.05.006","article-title":"Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer","volume":"270","author":"Tischkowitz","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.trecan.2022.04.009_bb0135","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1038\/onc.2014.443","article-title":"A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk","volume":"34","author":"Wang","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.trecan.2022.04.009_bb0140","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1074\/jbc.M009727200","article-title":"Characterization of tumor-associated Chk2 mutations","volume":"276","author":"Wu","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2022.04.009_bb0145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.dnarep.2004.03.033","article-title":"The Chk2 protein kinase","volume":"3","author":"Ahn","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.trecan.2022.04.009_bb0150","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2022.04.009_bb0155","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.04.009_bb0160","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1097-2765(02)00527-0","article-title":"Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2","volume":"9","author":"Li","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.trecan.2022.04.009_bb0165","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/MCB.24.2.708-718.2004","article-title":"Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair","volume":"24","author":"Zhang","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.trecan.2022.04.009_bb0170","doi-asserted-by":"crossref","first-page":"18937","DOI":"10.1074\/jbc.M111.313262","article-title":"Roles of Kruppel-associated box (KRAB)-associated co-repressor KAP1 Ser-473 phosphorylation in DNA damage response","volume":"287","author":"Hu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.trecan.2022.04.009_bb0175","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019101801","article-title":"DNA damage kinase signaling: checkpoint and repair at 30 years","volume":"38","author":"Lanz","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2022.04.009_bb0180","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1093\/emboj\/20.13.3544","article-title":"The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1\/Rad53 kinase cascade during growth and in response to DNA damage","volume":"20","author":"Zhao","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.trecan.2022.04.009_bb0185","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41588-018-0122-z","article-title":"Multiplex assessment of protein variant abundance by massively parallel sequencing","volume":"50","author":"Matreyek","year":"2018","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0190","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1038\/s41467-019-13194-2","article-title":"Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2","volume":"10","author":"Boonen","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2022.04.009_bb0195","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/35103059","article-title":"CHK2 kinase \u2013 a busy messenger","volume":"2","author":"Bartek","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.trecan.2022.04.009_bb0200","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","article-title":"Accurate classification of BRCA1 variants with saturation genome editing","volume":"562","author":"Findlay","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.04.009_bb0205","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/humu.23818","article-title":"Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification","volume":"40","author":"Parsons","year":"2019","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.trecan.2022.04.009_bb0210","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.ajhg.2021.09.003","article-title":"Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: a powerful approach","volume":"108","author":"Caputo","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0215","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci","volume":"551","author":"Michailidou","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2022.04.009_bb0220","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jmedgenet-2016-103839","article-title":"PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS","volume":"53","author":"Southey","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.trecan.2022.04.009_bb0225","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1158\/0008-5472.CAN-21-1845","article-title":"Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk","volume":"82","author":"Boonen","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2022.04.009_bb0230","article-title":"Mind the gap: preventing circularity in missense variant prediction","author":"Heijl","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.trecan.2022.04.009_bb0235","article-title":"White paper: the helix pathogenicity prediction platform","author":"Vroling","year":"2021","journal-title":"ArXiv"},{"key":"10.1016\/j.trecan.2022.04.009_bb0240","doi-asserted-by":"crossref","first-page":"E5189","DOI":"10.1073\/pnas.1511585112","article-title":"Comparison of predicted and actual consequences of missense mutations","volume":"112","author":"Miosge","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.trecan.2022.04.009_bb0245","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.1093\/nar\/gkz780","article-title":"A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor","volume":"47","author":"Rodrigue","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.trecan.2022.04.009_bb0250","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajhg.2018.07.016","article-title":"A multiplex homology-directed DNA repair assay reveals the impact of more than 1,000 BRCA1 missense substitution variants on protein function","volume":"103","author":"Starita","year":"2018","journal-title":"Am. J. Hum. Genet."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803322000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803322000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:52:54Z","timestamp":1778881974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803322000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2405803322000966"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2022.04.009","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHEK2 variants: linking functional impact to cancer risk","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2022.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}